Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire August 4, 2023

Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update

PR Newswire August 3, 2023

Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023

PR Newswire July 20, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire July 7, 2023

Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference

PR Newswire June 7, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire June 6, 2023

Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

PR Newswire May 22, 2023

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"

PR Newswire May 8, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire May 5, 2023

Insmed Reports First Quarter 2023 Financial Results and Provides Business Update

PR Newswire May 4, 2023

Insmed to Host Investor and Analyst Event on May 8, 2023

PR Newswire April 24, 2023

Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023

PR Newswire April 20, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire April 6, 2023

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis

PR Newswire March 31, 2023

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference

PR Newswire March 24, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire March 3, 2023

Insmed To Present at Two March Conferences

PR Newswire March 1, 2023

Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

PR Newswire February 23, 2023

Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023

PR Newswire February 9, 2023

Insmed To Present at the SVB Securities Global Biopharma Conference

PR Newswire February 7, 2023